ASCO 2020 annual meeting goes virtual

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The annual meeting of the American Society of Clinical Oncology will go virtual this year, the society announced March 24.

“As public health safety measures related to COVID-19 extend, the ASCO board has concluded that the annual meeting, scheduled for May 29-June 2 in Chicago, cannot occur in person as planned,” ASCO said in a statement.

“That is why we still intend to deliver the latest cancer science to the global community during the annual meeting timeframe using a virtual format that respects the contributions of the authors and the work of the Scientific Program Committee,” the statement said. “Information on the format, dates, specific content, registration, refunds, and many other details will be available in the coming weeks and posted on am.asco.org.”

Abstracts will be published online and in the Journal of Clinical Oncology, though ASCO’s educational program will not take place within the virtual annual meeting setting.

“As we confront this extraordinary situation, the health and safety of members, staff, and individuals with cancer—in fact, the entire cancer community—is ASCO’s highest priority,” Richard L. Schilsky, executive vice president and chief medical officer of ASCO, wrote a guest editorial in The Cancer Letter March 18 (The Cancer Letter, March 18).

ASCO’s statement on its virtual annual meeting is posted here.

Table of Contents

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.
The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login